Peer-influenced content. Sources you trust. No registration required. This is HCN.
Monthly Prescribing Reference (MPR)
Clinical trials of abaloparatide, a human parathyroid hormone related peptide analog, showed significantly increased bone mineral density at 12 months in the lumbar spine and femoral neck in men with osteoporosis.
Clinical Pharmacology January 30th 2023
The New England Journal of Medicine
In this study, more than 12,000 patients 18 years and older with hospitalization for extremity fracture were randomized to LWMH or aspirin. Rates of DVT were 1.7% and 2.5%, respectively. PE, bleeding complications, and other SAEs were similar across groups. Death occurred in 0.73% and 0.78% respectively for LWMH and aspirin.
Hematology January 25th 2023
OBR Oncology
Patients with newly diagnosed acute myeloid leukemia (AML) have had better results thanks to alterations to cytarabine/anthracycline-based intense chemotherapy, including the addition of high-dose cytarabine and adjustments to the dosage schedule or type of anthracycline.
Hematology January 23rd 2023
Blood
In conclusion, daratumumab (Darzalex) (D) was added to lenalidomide, bortezomib, and dexamethasone (RVd) in NDMM patients who were transplant-eligible, and this led to enhanced stringent complete response (sCR) and minimal residual disease (MRD)-negative rates, a tolerable safety profile, and no clinically meaningful effects on stem cell mobilization or engraftment. These findings suggest that the D-RVd combination may become a new standard of care for NDMM who are transplant-eligible.
Oakstone Publishing
Acquired/congenital bone marrow failure, thalassemia/hemoglobinopathies, transfusion medicine, new therapies (pharmacology), infections of the immunocompromised, hematologic malignancies (acute/chronic leukemias; myeloma/lymphomas), thoracic oncology (head/neck/lung/thyroid), and many other practice improvement areas are covered in this CME activity worth up to 41.25 credits. The video curriculum starts at $1,795 in price.
Hematology Advisor
According to a University of Washington research, only 40% of rural counties nationally had at least one licensed physician who could prescribe buprenorphine in 2016. The analysis discovered that by 2020, that number had increased to 63%. The increase was attributed by the study to modifications in federal regulations that permit NPs, PAs, and other healthcare professionals to prescribe buprenorphine. Only doctors could perform this in the past, and many remote counties lacked any. In 2002, Suboxone received approval from federal regulators, providing a new option for addiction treatment in communities without methadone facilities. Marshalltown, a town of 27,000 people encircled by rural areas, offers a feasible alternative, according to Andrea Storjohann, NP.
Family Medicine/General Practice January 23rd 2023